Menu Close

人類乳頭瘤病毒(Human Papilloma Virus, HPV)有200多種病毒,是常見通過性接觸傳播的病毒。
不同病毒種類的HPV感染會引發不同病症,HPV的病毒種類可分為高危型HPV和低危型HPV 。

高危型HPV可引致癌症。感染某些高危型HPV,例如HPV16和18,可導致約90%子宮頸癌及約90%肛門癌。另外,約70%相關口咽癌等頭頸癌亦由高危型HPV引起。

低危型HPV儘管不會引致癌症,但卻能引致生殖器官濕疣(俗稱椰菜花),超過90%椰菜花是由HPV 6及11引起的。

大部分的HPV感染通常不會有症狀,潛伏期可高達10年,更會人傳人。現時仍然沒有HPV感染的針對性治療方法,若無法自行清除HPV,HPV持續感染會演變成難以控制及相當嚴重的情況,例如導致癌症。

癌症種類HPV感染百分比
肛門癌>90%
子宮頸癌大部分
生殖器官濕疣(椰菜花)90%
陰道癌75%
外陰癌70%
口咽癌70%

GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.

GARDASIL 9 has not been demonstrated to provide protection against diseases caused by:

  • HPV types not covered by the vaccine
  • HPV types to which a person has previously been exposed through sexual activity

Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.

GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).

Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.